There would be a lot to unpack in that story. If I could come to the current one, the fact is that we are using mRNA technologies, which, quite frankly, up until the time of this pandemic, lots of time and effort had been put into, but there had not been a product commercialized, so we did not have facilities with large-scale RNA.
I think it's very fortunate for the world that BioNTech and Moderna and then BioNTech with Pfizer were able to have these facilities in place so they could pivot them. In some respects, that's really happenstance—and, as they say, happenstance for the good fortune of the world. There were not facilities sitting idly by ready to do that in the case of our existing facilities, including GSK's flu facility in Quebec. They're making vaccines against existing diseases and would not have been able to pivot quickly.